Startup Originals Team
Redcliffe Labs has acquired Pune-based Megavision Diagnostics Centre in a deal valued at around ₹40 crore, strengthening its presence in radiology and advanced medical imaging. The acquisition marks a move beyond Redcliffe’s established pathology business towards integrated diagnostics.
The transaction will add two diagnostic centres in Pune’s Pimpri-Chinchwad region to Redcliffe’s network. The centres offer imaging and diagnostic services including MRI, CT scans, sonography, ECG and mammography.
The acquisition is part of Redcliffe Labs’ broader inorganic expansion strategy as the company looks to build a larger diagnostics platform combining pathology, radiology and other clinical services.
What Happened?
Redcliffe Labs has acquired Megavision Diagnostics Centre, a Pune-based diagnostic business founded in 1996. The company operates two centres in the Pimpri and Nigdi areas of Pimpri-Chinchwad.
The transaction has been reported at approximately ₹40 crore, although the purchase price was not disclosed in Redcliffe’s formal announcement. Megavision generates around ₹20 crore in annual revenue, according to Redcliffe.
For Redcliffe, the acquisition provides an immediate entry into advanced imaging infrastructure rather than requiring the company to build new radiology centres from the ground up.
Redcliffe cofounder and CEO Aditya Kandoi said the deal will allow the company to add MRI, CT scans, ECG, EEG and mammography to its diagnostic offering.
Key Details
Megavision has operated in Pune for around three decades and has developed a strong presence in diagnostic imaging. Its two centres are equipped to provide several radiology and diagnostic services, including MRI and CT scans.
Redcliffe plans to retain Megavision’s existing workforce as part of the transaction. This is expected to help preserve operational continuity and maintain the centre’s existing relationships with patients and healthcare providers.
The acquisition also gives Redcliffe access to established imaging infrastructure at a time when the company is expanding beyond pathology. Radiology is generally more capital-intensive than pathology because it requires expensive equipment, specialised facilities and trained clinical personnel.
Megavision founder and director Kedar Prabhakar Bhate will continue to lead the business. He will also work with Redcliffe’s Clinical Board as the company expands its radiology operations in Pune and surrounding areas.
The deal follows other acquisitions by Redcliffe as it pursues an inorganic growth strategy. The company has been using acquisitions to add established diagnostic infrastructure and strengthen its presence in regional markets.
Company Background
Redcliffe Labs is an omnichannel diagnostics company founded in 2018 by Aditya Kandoi and Dheeraj Jain. The company initially built its business around pathology and home sample collection before expanding its broader diagnostics network.
Redcliffe currently offers more than 3,600 diagnostic tests and operates across more than 220 cities, with over 80 advanced laboratories, according to its website. The company says it has served more than 1 crore customers.
Its services include laboratory testing, preventive health packages, home sample collection and technology-enabled diagnostic services. The company has also been investing in AI-led tools and digital healthcare capabilities.
The Megavision acquisition adds a different layer to this existing model by bringing advanced imaging capabilities directly into Redcliffe’s network.
Industry Impact
The acquisition highlights the growing importance of consolidation in India’s diagnostics industry. Companies with established pathology networks are increasingly looking to add radiology and imaging services to provide patients with a wider range of diagnostic services through a single platform.
For Redcliffe, combining pathology with radiology could help increase the number of services it can provide to patients while making better use of its existing customer and healthcare-provider network.
The move also strengthens Redcliffe’s position in Pune, one of India’s major urban healthcare markets. Rather than entering the market only through new facilities, the acquisition gives the company access to existing centres, infrastructure and an established local presence.
For patients, an integrated diagnostics model could make it easier to access laboratory tests and imaging services through the same healthcare provider.
Future Plans
Redcliffe’s acquisition strategy indicates that the company plans to continue expanding its diagnostic capabilities through a combination of organic growth and acquisitions.
The company has recently been expanding its presence in Tier 2 and Tier 3 markets while adding advanced imaging capabilities to its network. Its broader objective is to create an integrated diagnostics platform that combines pathology with radiology and other specialised services.
The Megavision deal is therefore not just a geographic expansion into Pune. It also represents a strategic shift towards a broader diagnostic model in which Redcliffe can provide both laboratory testing and advanced imaging services.
Conclusion
The Redcliffe Labs acquisition of Megavision Diagnostics for around ₹40 crore strengthens the company’s move from a pathology-focused diagnostics provider towards an integrated healthcare diagnostics platform.
With two Pune centres, MRI and other imaging capabilities, an experienced workforce and an established local presence, Megavision gives Redcliffe an immediate radiology footprint in the region.
As Redcliffe continues pursuing acquisitions and expanding its diagnostic network, the company’s ability to combine pathology, radiology and technology could become an important part of its growth strategy.
